Cost-effectiveness of the anti-fibrotics for the treatment of idiopathic pulmonary fibrosis in the United States
Abstract Background The anti-fibrotic medications nintedanib and pirfenidone were approved in the United States for use in patients with idiopathic pulmonary fibrosis several years ago. While there is a growing body of evidence surrounding their clinical effectiveness, these medications are quite ex...
Na minha lista:
| Principais autores: | , , , , |
|---|---|
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
BMC
2022-01-01
|
| Serier: | BMC Pulmonary Medicine |
| Fag: | |
| Online adgang: | https://doi.org/10.1186/s12890-021-01811-0 |
| Tags: |
Ingen Tags, Vær først til at tagge denne postø!
|